ProQR Achieves First Clinical Validation of Axiomer RNA Editing Platform in Phase 1 AX-0810 Study

For CDMOs and plant operations teams beginning to map capacity for next-generation modalities, ProQR Therapeutics has delivered the first clinical proof-of-concept for its Axiomer RNA editing platform, with Phase 1 data from AX-0810 confirming dose-dependent target engagement in healthy volunteers across all key biomarkers.

In the evaluable 3 mg/kg and 6 mg/kg cohorts, AX-0810 produced up to an 8-fold change in total serum bile acids, clearing the 2-fold threshold ProQR had pre-specified as a meaningful indicator of NTCP modulation. Concordant readouts across bile acid profile and TUDCA markers reinforce the signal. No serious adverse events or pruritus were reported, and pharmacokinetic data indicate a half-life of approximately eight weeks, supporting sustained target engagement from infrequent dosing.

The manufacturing and quality implications of that PK profile are not trivial. An eight-week half-life in an RNA-based therapeutic points toward a highly stable molecular architecture, but it also raises process validation questions around characterisation assays, reference standards, and comparability protocols that ICH Q10-aligned quality systems will need to address as the platform scales. RNA editing constructs occupy a regulatory space that existing oligonucleotide guidance only partially covers, meaning QA directors should expect iterative dialogue with agencies on analytical method qualification.

ProQR has indicated the NTCP biomarker findings support advancement of next-generation candidate AX-0811 and future clinical studies in biliary atresia, a rare paediatric indication with limited therapeutic options. For CDMOs evaluating platform fit, the transition from AX-0810 to AX-0811 will serve as an early test of whether Axiomer's manufacturing process is sufficiently platform-like to enable technology transfer without full revalidation at each iteration.

The Phase 1 study in healthy volunteers remains ongoing; full pharmacokinetic and safety datasets, expected at a later data cut, will be the more consequential checkpoint for organisations modelling GMP readiness for this modality.

Source: ProQR Therapeutics via company press release, 25 June 2026.